Q2 saw modest sales growth and strong performance from key brands, but net income and free cash flow declined due to higher taxes and interest. Full-year guidance was reaffirmed, with continued pipeline progress and strategic acquisitions strengthening future prospects.Original document: Novartis A…
Q2 saw modest sales growth and strong performance from key brands, but net income and free cash flow declined due to higher taxes and interest. Full-year guidance was reaffirmed, with continued pipeline progress and strategic acquisitions strengthening future prospects.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.